Clinical trial
A Phase I/Ib, Dose Escalation Study to Evaluate Safety and Efficacy of RP6530, a Dual PI3K δ/γ Inhibitor, in Patients With Relapsed or Refractory T-cell Lymphoma
NCT02567656 is registered in ClinicalTrials.gov with Rhizen Pharmaceuticals SA as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase I/Ib, Dose Escalation Study to Evaluate Safety and Efficacy of RP6530, a Dual PI3K δ/γ Inhibitor, in Patients With Relapsed or Refractory T-cell Lymphoma
- Lead sponsor
- Rhizen Pharmaceuticals SA
- Phase
- Phase 1
- Overall status
- Completed
- Start date
- September 30, 2015
- Completion date
- December 10, 2018
- Enrollment
- 58 (actual)
- Sites
- 8
Conditions
As the registry lists them; a condition with its own page is linked.